Latest drug discovery Stories

Selexis SA Launches SURE CHO-Mplus™ Libraries

2013-04-17 23:04:13

Technology Addresses Secretion Bottlenecks in Recombinant Protein Expression. Geneva, Switzerland (PRWEB) April 17, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification, cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the launch of its novel platform, SURE CHO-Mplus™ Libraries, which were designed and constructed to address a broad range of issues surrounding recombinant protein secretion...

Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium

2013-04-17 12:26:01

SAN DIEGO, April 17, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that two posters for its lead product candidate, MST-188, were presented at the 7(th) Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami. Brian M. Culley, Chief Executive Officer, said: "Increasing evidence suggests that transfusion of 'older' red blood cells (RBC) impairs clinical outcomes as a result of defects resulting from storage or age....

Xenon Exclusively Licenses to Merck Compounds for a Novel Target for Cardiovascular Disease

2013-04-17 08:28:40

VANCOUVER, British Columbia, April 17, 2013 /PRNewswire/ -- Xenon announced that Merck, known as MSD outside the United States and Canada, through an affiliate, has exercised its option to exclusively license small molecule compounds for a novel target for the potential treatment of cardiovascular disease. In 2009, Xenon and Merck entered into a strategic alliance where Xenon employed its human clinical genetics platform to validate novel cardiovascular targets and collaborated on the...

ViS selected to present at TEDMED 2013

2013-04-16 12:26:52

-- Conference recognizes unique platform that promises to revolutionize clinical trial planning WASHINGTON, April 16, 2013 /PRNewswire/ -- TEDMED's Hive brings together medical innovators who are most likely to impact the future of human health. ViS was selected based on the way it tackles fundamental issues in medical innovation with collaborative approaches. (Logo: http://photos.prnewswire.com/prnh/20130416/NY94958LOGO ) Medical innovation relies on clinical research to...

Heptares to Present at Upcoming Scientific and Biotech Industry Conferences

2013-04-16 08:28:14

WELWYN GARDEN CITY, England and BOSTON, April 16, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, notes that it will be presenting at the following scientific conferences and biotech industry events over the coming weeks. 8th Annual Drug Discovery Chemistry [http://www.drugdiscoverychemistry.com/GPCR-Drug-Design ] (San Diego, CA, USA, April 16-18) Dr Rob Cooke, Heptares' Head of Biomolecular Structure, will give a...

MetaStat Appoints David Epstein, Ph.D. as Advisor to Lead Drug Discovery

2013-04-15 08:30:15

MONTCLAIR, N.J., April 15, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today the appointment of David Epstein, Ph.D. as Advisor for MetaStat's Drug Discovery & Development efforts. In addition, MetaStat intends to appoint Dr. Epstein to MetaStat's board of directors as soon as practicable. Dr. Epstein brings tremendous expertise to MetaStat at a pivotal time in the company's evolution....

Selexis SA to Partner and Exhibit at BIO 2013

2013-04-10 23:03:17

Selexis to Meet with Companies Interested in Protein Drug Discovery, Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing. Geneva, Switzerland (PRWEB) April 10, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO International...

HurelStaticDog(TM), Hurel Corporation's In Vitro Cell Culture of Canine (Dog) Liver Cells, to be Presented at Toxicology Conference in Barcelona, April 11

2013-04-10 08:32:44

Data Highlight Benefits of New Tool for Predicting Drug Toxicity in Humans Before Clinical Trials Begin -- Important Milestone in Drug Development Evolution NORTH BRUNSWICK, N.J., April 10, 2013 /PRNewswire/ -- Hurel Corporation ("Hurel") today announced that the results of toxicological evaluations performed on HurelStaticDog(TM), Hurel's new, patent-pending method of culturing actual liver cells from the canine (dog) species, will be highlighted as a part of UCB's keynote overview...

Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis

2013-04-10 08:30:35

- Adds to Earlier Data Demonstrating Potential to Restore Myelin in MS Patients - SEATTLE, April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled...

Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs

2013-04-08 20:22:25

American Testing Lab and Indian Consulting Firm Work to Broaden Acceptance of the BCS EXTON, Pa., April 8, 2013 /PRNewswire/ -- The preclinical contract research organization Absorption Systems, a global leader in pharmacokinetic testing of drugs, announces that it has entered into a partnership with the Indian pharmaceutical consulting firm Synerzys Lifecare Pvt Ltd. The intent of the partnership is two-fold: to sell Absorption Systems' services in India and, more broadly, to expand...